Thrombophilia evaluation in pulmonary embolism

Area of Science:

• Medical Science
• Hematology
• Genetics

Background:

• Pulmonary embolism patients frequently undergo thrombophilia evaluation for risk stratification and treatment planning.
• The clinical utility of thrombophilia testing in various scenarios remains uncertain.
• Testing can be misinterpreted, leading to patient and clinician anxiety.

Purpose of the Study:

• Evaluate current recommendations for thrombophilia testing in venous thromboembolism (VTE) guidelines.
• Review recent literature on the clinical application of these recommendations.
• Examine novel genetic assessments and direct oral anticoagulant (DOAC) use in VTE patients with thrombophilias.

Main Methods:

• Review of current VTE guidelines.
• Analysis of recent literature on thrombophilia testing.
• Evaluation of novel genomic assessments.
• Assessment of studies on DOACs in VTE patients with thrombophilias.

Main Results:

• Current VTE guidelines suggest limited use of thrombophilia testing due to misinterpretation and lack of management change.
• Testing and results can cause anxiety.
• Innovative techniques and expanded genomic assessments are emerging.
• Literature on DOAC appropriateness for VTE patients with hereditary thrombophilias or antiphospholipid syndrome is growing.

Conclusions:

• Current thrombophilia testing has limited impact on clinical management and outcomes for most VTE patients.
• Testing should be used judiciously, only when it is likely to alter management.
• Future genomic testing and anticoagulant studies may enhance the utility of thrombophilia testing.